tirzepatide osa fda FDA Approves Zepbound for Moderate-to-Severe Obstructive Sleep Apnea and Obesity

FDA approves weight loss drug found in Mounjaro for use in sleep apnea patients

27.29

★★★★☆4.8 (126)

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

29.32

★★★★★4.9 (98)

The FDA has just approved Zepbound (tirzepatide), the first medication designed to treat both obstructive sleep apnoea (OSA) and obesity simultaneously. In clinical trials, Zepbound helped reduce breathing disruptions by 50% and

29.45

★★★★★5.0 (157)

Breakthrough Treatment for Obstructive Sleep Apnea: FDA Approves Zepbound ( Tirzepatide)

24.03

★★★★★4.7 (84)

On Nov 8 the FDA approved #tirzepatide for chronic weight management in people with obesity or overweight with weight-related conditions. Here's what to know about #Zepbound, the latest antiobesity drug. https://ja.ma/3NnD3VY #MedicalNews

21.20

★★★★★4.9 (203)

Huge news: FDA has approved Zepbound (tirzepatide- GLP-1/GIP receptor agonist) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity. As a cardiologist, this is a huge deal

21.70

★★★★★5.0 (176)

The FDA Helps Bring Greater Attention to Sleep Apnea with Zepbound

27.81

★★★★★4.8 (132)